食道がん治療の世界市場：2025年～2033年

治療オプションの進歩が食道がん治療の市場規模の拡大を大きく後押ししており、予測期間中も市場を牽引するとみられます。化学療法は、特に進行性・転移性の患者に対する治療の基幹であることに変わりはありません。しかし、化学療法と、より新しい免疫療法や標的薬剤を用いた先行化学療法後に行う必要のある治療法の併用は、治療アプローチに革命をもたらしています。

例えば、2024年3月、BeiGene, Ltd.は、PD-（L）1阻害剤を含まない全身化学療法歴のある切除不能または転移性食道扁平上皮がん（ESCC）の成人患者に対する単剤療法として、TEVIMBRA（tislelizumab-jsgr）が米国食品医薬品局（FDA）から承認されたことを発表しました。

免疫療法は、進行食道がん患者、特に化学療法や放射線療法のような従来の治療に反応しない患者にとって、画期的な治療法として登場しました。例えば、ペムブロリズマブ（キイトルーダ）やニボルマブ（オプジーボ）などの薬剤は、進行食道がん患者、特にPD-L1が高発現している患者の生存率を有意に改善しています。

化学療法、免疫療法、標的治療などの食道がん治療の進歩は患者の治療に革命をもたらしましたが、これらの薬剤に伴う副作用が食道がん治療市場の成長を大きく妨げています。これらの副作用はしばしば治療の中断、患者のコンプライアンス低下、ヘルスケアコストの増加につながり、これらすべてが市場全体の可能性を妨げています。

化学療法は、特に進行期の食道がん治療の主軸であることに変わりはありません。しかし、シスプラチン、カルボプラチン、フルオロウラシルなどの化学療法薬には重篤な副作用が伴い、患者のQOLや治療プロトコルの遵守に大きな影響を与えます。重篤な副作用のために化学療法を中断する患者は30～40%に達し、治療効果が低下することが研究で示されています。

ペムブロリズマブ（キイトルーダ）やニボルマブ（オプジーボ）などの免疫療法薬は、進行食道がん患者の生存率を有意に改善しました。しかし、これらの治療薬には治療を複雑にするさまざまな免疫関連の副作用も伴う。免疫療法薬は、体の免疫系が自分自身の組織を攻撃する自己免疫疾患を誘発する可能性があり、大腸炎、肺炎、肝炎などを引き起こします。

当レポートでは、世界の食道がん治療市場について調査し、市場の概要とともに、がんタイプ別、治療タイプ別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブの洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界の展望

• 市場のリーダーと先駆者
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 食道がん治療市場（がんタイプ別）

• 扁平上皮がん
• 腺がん

第6章 食道がん治療市場（治療タイプ別）

• 手術
• 化学療法
• 放射線治療
• 標的薬物療法
• 免疫療法
• 併用療法
• その他

第7章 食道がん治療市場（エンドユーザー別）

• 病院
• 専門クリニック
• 外来手術センター
• 学術研究機関
• その他

第8章 食道がん治療市場、地域別市場分析と成長機会

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他
• 中東・アフリカ

第9章 競合情勢と市場ポジショニング

第10章 企業プロファイル

• Merck &Co., Inc.
• Bristol-Myers Squibb Company
• BeiGene, Ltd.
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Daiichi Sankyo, Inc.
• Taiho Oncology, Inc.
• Astellas Pharma Inc.
• Novartis AG
• Amgen, Inc.

第11章 仮定と調査手法

第12章 付録

The global esophageal cancer treatment market reached US$ 1.31 billion in 2024 and is expected to reach US$ 2.66 billion by 2033, growing at a CAGR of 8.2% during the forecast period 2025-2033.

Esophageal cancer is a neoplastic disease characterized by the uncontrolled proliferation of abnormal cells in the esophageal lining. It typically originates in the mucosal or submucosal layers and can invade deeper structures, including the muscularis propria and surrounding lymph nodes. It is an aggressive cancer with a high mortality rate, often diagnosed at an advanced stage due to a lack of early symptoms.

The demand for esophageal cancer treatment is driven by increasing incidence rates, advancements in treatment options and improving healthcare access. Esophageal cancer is one of the fastest-growing cancers worldwide, which increases the demand for advanced cancer therapeutics. For instance, according to the National Institute of Health (NIH), esophageal cancer is the ninth most common cancer and the sixth leading cause of cancer deaths worldwide. The global incidence of esophageal cancer is estimated at 500,000 new cases per year. The market is expected to witness robust growth in the coming years, although challenges like late-stage diagnosis, high treatment costs, and limited awareness continue to affect its growth.

Market Dynamics: Drivers & Restraints

Rising advancements in treatment options

The rising advancements in treatment options are significantly driving the growth of the esophageal cancer Treatment market and are expected to drive the market over the forecast period. Chemotherapy remains the backbone of treatment, especially for patients with advanced or metastatic disease. However, the combination of chemotherapy and the therapies that need to be given after prior chemotherapy with newer immunotherapy or targeted agents has revolutionized the approach to treatment.

For instance, in March 2024, BeiGene, Ltd. released that the U.S. Food and Drug Administration (FDA) approved TEVIMBRA (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.

Immunotherapy has emerged as a game-changer for patients with advanced esophageal cancer, especially those who are non-responsive to conventional treatments like chemotherapy and radiation. For instance, drugs such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo) have significantly improved survival rates in patients with advanced esophageal cancer, especially those with high PD-L1 expression.

Side effects associated with certain medications

While advancements in esophageal cancer treatments, such as chemotherapy, immunotherapy and targeted therapies, have revolutionized patient care, the side effects associated with these medications are significantly hampering the growth of the esophageal cancer treatment market. These adverse effects often lead to treatment discontinuation, lower patient compliance and increased healthcare costs, all of which hinder the overall market potential.

Chemotherapy remains a mainstay of treatment for esophageal cancer, especially in advanced stages. However, chemotherapy drugs such as cisplatin, carboplatin and fluorouracil come with severe side effects, which significantly impact patient quality of life and adherence to treatment protocols. Studies indicate that up to 30-40% of patients may discontinue chemotherapy due to severe side effects, reducing the effectiveness of treatment.

Immunotherapy drugs, such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo), have significantly improved survival rates in patients with advanced esophageal cancer. However, they also come with a range of immune-related side effects that can complicate treatment. Immunotherapy drugs can trigger autoimmune conditions, where the body's immune system attacks its own tissues, leading to colitis, pneumonitis and hepatitis.

Segment Analysis

The global esophageal cancer treatment market is segmented based on cancer type, treatment type, end-user and region.

Product Type:

The combination therapy segment is expected to dominate the esophageal cancer treatment market share

Combination therapy, especially the combination of chemotherapy and immunotherapy, has led to improved survival rates and better outcomes for patients, particularly in advanced stages of esophageal cancer. By combining different treatment types, it is possible to tackle cancer through multiple mechanisms, enhancing its effectiveness and reducing the likelihood of drug resistance.

For instance, in May 2022, Bristol Myers Squibb cleared the U.S. Food and Drug Administration (FDA) approval for both Opdivo (nivolumab) (injection for intravenous use) in combination with fluoropyrimidine- and platinum-containing chemotherapy and Opdivo plus Yervoy (ipilimumab) as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 status.

A clinical trial of the combination of Nivolumab (Opdivo), a PD-1 inhibitor, and chemotherapy demonstrated a significantly longer overall survival (OS) and progression-free survival (PFS) in patients with advanced esophageal squamous cell carcinoma (ESCC) compared to chemotherapy alone. The success of combination therapies like Nivolumab + chemotherapy has led to a shift toward combination treatment protocols in clinical practice, making combination therapy the dominant treatment option in advanced esophageal cancer cases.

Geographical Analysis

North America is expected to hold a significant position in the esophageal cancer treatment market share

North America benefits from highly developed healthcare systems, with state-of-the-art medical facilities, specialized cancer centers and advanced treatment technologies. This infrastructure enables early diagnosis, early-stage treatment and access to the latest therapeutic innovations. The United States is home to top-tier cancer centers such as MD Anderson Cancer Center, Johns Hopkins, and Memorial Sloan Kettering Cancer Center, which are at the forefront of esophageal cancer research and treatment.

The incidence of esophageal cancer in North America, particularly in the United States, has been rising due to lifestyle factors such as obesity, acid reflux and tobacco consumption. This increase in esophageal cancer cases directly contributes to the demand for effective treatments. For instance, according to the National Institute of Health (NIH), it is estimated that 20,640 new cases of esophageal cancer diagnosed in the United States in 2022, with an estimated 16,410 deaths. The growing incidence rate of esophageal cancer in North America drives the demand for treatment options, particularly immunotherapies, chemotherapies, and surgical interventions.

North America hosts a large number of pharmaceutical companies involved in the research, development, and commercialization of esophageal cancer treatments. Major global pharmaceutical companies like Roche, Bristol-Myers Squibb, and Merck have a strong market presence in the region. For instance, Merck's Pembrolizumab (Keytruda) is one of the leading immunotherapies used in esophageal cancer and has gained widespread use in North America for advanced-stage esophageal squamous cell carcinoma. Roche's Herceptin (Trastuzumab) is commonly used for HER2-positive esophageal cancer in the U.S., and its combination with chemotherapy is widely adopted.

Asia-Pacific is growing at the fastest pace in the esophageal cancer treatment market

The Asia Pacific region has the highest incidence of esophageal cancer, particularly in countries like China, India, and Japan, where esophageal squamous cell carcinoma is more common. Lifestyle factors, such as smoking, alcohol consumption, and poor diet, combined with genetic predispositions and infections like HPV, contribute to the high rates of esophageal cancer in this region.

For instance, according to the National Institute of Health (NIH), China is the most common country for esophageal cancer, which accounts for approximately 50% of global incidence and death cases annually. In India, the age-standardized incidence rate of esophageal cancer is high, driven by factors like tobacco use, alcohol consumption, and dietary factors. The high burden of esophageal cancer in the Asia Pacific region significantly drives the demand for early diagnosis and effective treatment options, leading to rapid market growth.

The availability of innovative therapies like immunotherapy (e.g., Pembrolizumab, Nivolumab) and targeted therapies (e.g., Trastuzumab) in Asia Pacific countries has been a significant factor in the region's market expansion. Many APAC countries have started integrating advanced cancer treatments into their healthcare systems, especially for advanced esophageal cancer.

For instance, recently, in China, the National Medical Products Administration (NMPA) has approved immunotherapies like Toripalimab (Envafolimab) making them accessible to patients with advanced esophageal cancer. The availability of approved and locally approved immunotherapies and targeted therapies has significantly improved the treatment landscape in the Asia Pacific region, contributing to the rapid growth of the esophageal cancer treatment market.

Competitive Landscape

The major global players in the esophageal cancer treatment market include Merck & Co., Inc., Bristol-Myers Squibb Company, BeiGene, Ltd., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Daiichi Sankyo, Inc., Taiho Oncology, Inc., Astellas Pharma Inc., Novartis AG, Amgen, Inc. and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global esophageal cancer treatment market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 146 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Cancer Type
• 2.4. Snippet by Treatment Type
• 2.5. Snippet by End-User
• 2.6. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Rising Advancements in Treatment Options
  • 3.1.2. Restraints
    • 3.1.2.1. Side Effects Associated with Certain Medications
  • 3.1.3. Opportunity
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. Latin America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Force Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Esophageal Cancer Treatment Market, By Cancer Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 5.1.2. Market Attractiveness Index, By Cancer Type
• 5.2. Squamous Cell Carcinoma*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Adenocarcinoma

6. Esophageal Cancer Treatment Market, By Treatment Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 6.1.2. Market Attractiveness Index, By Treatment Type
• 6.2. Surgery*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Chemotherapy
• 6.4. Radiation Therapy
• 6.5. Targeted Drug Therapy
• 6.6. Immunotherapy
• 6.7. Combination Therapy
• 6.8. Others

7. Esophageal Cancer Treatment Market, By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Specialty Clinics
• 7.4. Ambulatory Surgical Centers
• 7.5. Academic and Research Institutes
• 7.6. Others

8. Esophageal Cancer Treatment Market, By Regional Market Analysis and Growth Opportunities

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.6.1. U.S.
    • 8.2.6.2. Canada
    • 8.2.6.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.6.1. Germany
    • 8.3.6.2. U.K.
    • 8.3.6.3. France
    • 8.3.6.4. Spain
    • 8.3.6.5. Italy
    • 8.3.6.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.6.1. Brazil
    • 8.4.6.2. Argentina
    • 8.4.6.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.6.1. China
    • 8.5.6.2. India
    • 8.5.6.3. Japan
    • 8.5.6.4. South Korea
    • 8.5.6.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Merck & Co., Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
  • 10.1.5. SWOT Analysis
• 10.2. Bristol-Myers Squibb Company
• 10.3. BeiGene, Ltd.
• 10.4. F. Hoffmann-La Roche Ltd.
• 10.5. Eli Lilly and Company
• 10.6. Daiichi Sankyo, Inc.
• 10.7. Taiho Oncology, Inc.
• 10.8. Astellas Pharma Inc.
• 10.9. Novartis AG
• 10.10. Amgen, Inc.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us